Journal
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
Volume 140, Issue 6, Pages 838-844Publisher
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPE4PK6CTBNQJY
Keywords
Merkel cell carcinoma; Survival; Prognosis; p63
Categories
Funding
- American Cancer Society [RSG-08-115-01-CCE]
- National Institutes of Health [K24-CA139052, F30ES017385]
- David & Rosalind Bloom Endowment for MCC Research
- Michael Piepkorn Endowment Fund
- University of Washington MCC Patient Gift Fund
Ask authors/readers for more resources
Objectives: To determine the clinical utility of p63 expression, which has been identified in several cohorts as a predictor of poorer prognosis in Merkel cell carcinoma (MCC). Methods: Immunohistochemistry was used to determine p63 expression on MCC tumors from 128 patients. Results: Of the patients, 33% had detectable p63 expression. p63 Positivity was associated with an increased risk of death from MCC (hazard ratio, 2.05; P = .02) in a multivariate Cox regression model considering stage at presentation, age at diagnosis, and sex. Although p63 expression correlated with diminished survival in this largest cohort reported thus far, the effect was weaker than that observed in prior studies. Indeed, within a given stage, p63 status did not predict survival in a clinically or statistically significant manner. Conclusions: It remains unclear whether this test should be integrated into routine MCC patient management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available